<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study

<i>KRAS</i> and <i>BRAF</i> Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study

<i>KRAS</i> mutation is a confirmed predictive biomarker for anti-EGFR monoclonal antibody therapy response for metastatic colorectal cancer. However, its prognosis impact and the predictive potential for first-line standard chemotherapy remains unclear. On the other hand, V600E mutation...

Full description

Bibliographic Details
Main Authors: Nuria Garcia-Carbonero, Javier Martinez-Useros, Weiyao Li, Alberto Orta, Nuria Perez, Cristina Carames, Tatiana Hernandez, Irene Moreno, Gloria Serrano, Jesus Garcia-Foncillas
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cells
Subjects:
<i>kras</i>
<i>braf</i>
metastatic colorectal cancer
prognosis
chemotherapy
anti-egfr
biomarker
Online Access:https://www.mdpi.com/2073-4409/9/1/219

Internet

https://www.mdpi.com/2073-4409/9/1/219

Similar Items